On page 7, line 12, delete "issued" and substitute --is used-- therefor.

On page 7, line 24, delete "1,1-difuoro-" and substitute --1,1-difluoro- -- therefor.

On page 8, lines 1, 8 and 14, following "sufficient" please add --material--.

In the claims:

Please amend the claims as follows:

1. (twice amended) A medicament containing as active ingredients a physiologically acceptable salt of formoterol[, or a physiologically acceptable salt] or a solvate thereof, and budesonide [for inhalation treatment of respiratory disorders, and wherein said active ingredients may be delivered simultaneously or sequentially].

2. (twice amended) A pharmaceutical composition [for administration by inhalation for treatment of respiratory disorders] which [composition] comprises effective amounts of a physiologically acceptable salt of formoterol[, or a physiologically acceptable salt] or a solvate thereof, and budesonide, together with a pharmaceutically acceptable carrier.

7. (twice amended) A method for the treatment of asthma and other inflammatory respiratory disorders which [employs] comprises administering by inhalation to a host in need of such treatment effective amounts of a physiologically acceptable salt of formoterol[, or a physiologically acceptable salt] or a solvate thereof, and budesonide [for combination therapy and whereby formoterol and budesonide are simultaneously or sequentially administered by inhalation to a host in need of said treatment].

Please cancel claims 3, 5, 6, and 8-13.

Please add the following new claims:

--14. The medicament of claim 1 wherein the active ingredients are in dry powder form.

15. The medicament of claim 1 or 14 wherein the formoterol is in the form of the fumarate dihydrate.

16. The pharmaceutical composition of claim 2 wherein the formoterol is in the form of the fumarate dihydrate.

17. The method according to claim 7, wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-100 μg per day, and the effective amount of budesonide is 50-4800 μg per day.

18. The method according to claim 17 wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-48 μg per day, and the effective amount of budesonide is 100-1600 μg per day.

19. The method according to claim 7 wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:4 to 1:70.

20. The method according to any one of claims 7 and 17-19, wherein the administration is performed from a dry powder inhaler.

21. The method according to claim 20 wherein the inhaler is a Turbuhaler™.

22. The method according to any one of claims 7 and 17-19, wherein the administration is performed from a metered dose inhaler.